source
- GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent dealGSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
- White House withdraws Heidi Overton’s FDA commissioner nomination, raising uncertainty for agency’s futureThe White House pulled its nomination of Heidi Overton for FDA commissioner, a move that surprised members of the Senate health committee. Overton’s removal leaves the agency without a permanent h…